Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury

Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells, COVID-19 interferes with the production and secretion of the pulmonary surfactant and therefore causes an incre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Physiol Neurobiol
Main Authors: Cattel, Francesco, Giordano, Susanna, Bertiond, Cecilia, Lupia, Tommaso, Corcione, Silvia, Scaldaferri, Matilde, Angelone, Lorenzo, De Rosa, Francesco Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier B.V. 2021
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7916525/
https://ncbi.nlm.nih.gov/pubmed/33657448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.resp.2021.103645
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados